# Richard Ferrari

> Richard Ferrari is a Series B investor at DeNovo Ventures backing Health Care and Medical Device. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [DeNovo Ventures](https://shizune.co/investors/profile/denovo-ventures)
- Location: San Francisco, United States
- Total investments: 3
- Last investment: Feb 2011
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/richard-ferrari-8820701/

Richard Ferrari is a Series B investor at DeNovo Ventures in San Francisco focused on Health Care and Medical Device. Richard Ferrari is the Board Director of Spiracur Inc. He has been a successful CEO of several medical technology companies, both prior to and after co-founding De Novo Ventures in 2000. Following De Novo’s investment in CryoVascular Systems, Mr. Ferrari became CEO, growing the initial 5 person start up team to a company of 20 employees. Hewas instrumental in developing the clinical and product strategies and hiring the executive team. In 2002, Mr. Ferrari led Paracor Medical, another De Novo portfolio company. He grew the company from 4 to 22 employees, refined the product strategy, raised its Series B financing and hired his replacement CEO. Prior to co-founding De Novo Ventures, he was the co-founder and CEO of CardioThoracic Systems (“CTSI”), a company he led to an initial public offering in only 7 months in 1996. CTSI, the market leader in disposable instruments and systems for performing minimally invasive beating heart bypass surgery, was ultimately acquired by Guidant Corporation in November 1999. Before that, Mr. Ferrari was the CEO of Cardiovascular Imaging Systems (“CVIS”). As CEO, he orchestrated a successful IPO and ultimately sold the company to Boston Scientific Corporation in 1995.In addition, Mr. Ferrari founded Saratoga Ventures in 1996, a venture capital partnership that has provided seed financing to startup medical technology companies, including Atrionix, Oratec, Enteric Medical, Trivascular, and Endotex. At Saratoga, he was Chairman of Oratec, which was sold in 2001 to Smith & Nephew PLC. Mr. Ferrari also co-founded The Medical Technology Group, which spun out Integrated Vascular Systems, an early stage femoral artery closure company which was sold to Abbott and Angiosense, a needle-free, jet injection, local drug delivery company. Early in his career, Mr. Ferrari held the position of Executive Vice President and General Manager of ADAC Laboratories. He holds a BS Degree from Ashland University.An MBA from the University of South Florida.In addition to Spiracur, Mr. Ferrari sits on the boards of,Benvenue, CardioMind, MyoScience, Ovalis, Paracor Medical, Pulmonx, Simpirica, Spinal Kinetics,Spinal Modulation . His prior board involvement includes TriVascular.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 67% |
| Medical Device | 2 | 67% |
| Biotechnology | 1 | 33% |
| Manufacturing | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 1 | 33% |
| Series C | 1 | 33% |
| Debt Financing | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Spiracur | Spiracur Inc. is a privately held medical device company focused on the development of innovative wound healing technologies. Spiracur was founded out of the Stanford Biodesign Innovation Program in 2007. Its first product, the SNaP Wound Care System, grew out of the notion that current negative pressure wound therapies were too cumbersome forpatients and clinicians. Spiracur strives to develop products that are truly patient-centric. | $35M | Series C | Feb 01, 2011 |  |
| Spinal Kinetics | Spinal Kinetics is a privately-held medical device company focused on partnering with spine surgeons to develop innovative and practical motion preservation systems for treating degenerative diseases of the spine.The M6 artificial disc is the first of these non-fusion motion preservation products intended to replicate the anatomic andbiomechanical attributes of a natural intervertebral disc. The M6 is the only artificial disc that mimics a natural disc’s design by incorporating an artificial nucleus and annulus into both its cervical and lumbar platforms. | $5.3M | Debt Financing | Sep 21, 2009 |  |
| Spiracur | Spiracur Inc. is a privately held medical device company focused on the development of innovative wound healing technologies. Spiracur was founded out of the Stanford Biodesign Innovation Program in 2007. Its first product, the SNaP Wound Care System, grew out of the notion that current negative pressure wound therapies were too cumbersome forpatients and clinicians. Spiracur strives to develop products that are truly patient-centric. | $20.3M | Series B | Jun 29, 2009 |  |

3 of 3 investments shown.

## Co-investors
- [HLM Venture Partners](https://shizune.co/investors/profile/hlm-venture-partners) — VC Fund, 1 deal together
- [Maverick Ventures](https://shizune.co/investors/profile/maverick-ventures) — VC Fund, 1 deal together
- [MDS Capital](https://shizune.co/investors/profile/mds-capital) — VC Fund, 1 deal together
- [New Leaf Venture Partners](https://shizune.co/investors/profile/new-leaf-venture-partners) — VC Fund, 1 deal together
- [Pinnacle Ventures](https://shizune.co/investors/profile/pinnacle-ventures) — VC Fund, 1 deal together
- [Scale Venture Partners](https://shizune.co/investors/profile/scale-venture-partners) — VC Fund, 1 deal together

## About DeNovo Ventures

VC Fund · Saratoga, United States

DeNovo Ventures was formed in 2000 by seasoned investors and experienced medical device entrepreneurs who sought to share the lessons learned from a history of successful investing and building successful companies. They believed that their unique combination of skills and perspectives could help entrepreneurs to build companies which would havesignificant clinical impact and generate superior returns. Seven years later, this belief continues to hold true, demonstrated by investment success in selected medical device and biotechnology companies. With $650 million under management, De Novo has made more than 40 investments in medical devices and biotechnology across three funds. They invest in all stages of enterprise development and growth – from early stage to late stage. The unique background of leading companies as entrepreneurs and operating executives from start to exit enables us to advise entrepreneurs and management teams over the full life cycle of the company.

5 contacts available at DeNovo Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Richard Ferrari | Co - Founder & Managing Director | https://shizune.co/investors/profile/richard-ferrari |
| David M. Mauney | co-founder and Managing Director | https://shizune.co/investors/profile/david-m-mauney |
| Frederick Dotzler | Managing Director | https://shizune.co/investors/profile/frederick-dotzler |
| Jay Watkins | Managing Director | https://shizune.co/investors/profile/jay-watkins |
| Joe Mandato | Managing Director | https://shizune.co/investors/profile/joe-mandato |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Richard Ferrari invest in?

Richard Ferrari invests primarily in Health Care, Medical Device and Biotechnology startups, most often at Series B and Series C stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Richard Ferrari last invest?

The most recent investment recorded for Richard Ferrari closed in Feb 2011. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co